This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
mannich bases | 839 |
respiratory syndrome | 461 |
influenza virus | 444 |
public health | 442 |
ebola virus | 425 |
acute respiratory | 415 |
immune responses | 357 |
virus infection | 346 |
respiratory tract | 319 |
united states | 296 |
severe acute | 278 |
immune response | 264 |
infectious diseases | 252 |
cord uid | 244 |
doc id | 244 |
clinical signs | 240 |
mg kg | 234 |
present study | 230 |
avian influenza | 216 |
syndrome coronavirus | 215 |
amino acid | 214 |
cell lines | 209 |
infected cells | 209 |
mg ml | 207 |
type i | 205 |
risk factors | 203 |
time pcr | 203 |
ns pro | 199 |
respiratory syncytial | 198 |
gene expression | 197 |
immune system | 192 |
syncytial virus | 191 |
middle east | 188 |
viral infections | 187 |
reference drug | 180 |
respiratory viruses | 171 |
innate immune | 170 |
health care | 168 |
viral infection | 165 |
viral load | 164 |
escherichia coli | 160 |
performed using | 160 |
mhc class | 152 |
mannich base | 151 |
east respiratory | 149 |
class i | 147 |
dendritic cells | 146 |
infectious bronchitis | 145 |
viral replication | 145 |
amino acids | 145 |
viral rna | 144 |
rna viruses | 144 |
bone marrow | 142 |
porcine epidemic | 142 |
clinical trials | 139 |
may also | 137 |
staphylococcus aureus | 137 |
virus replication | 137 |
cleavage sites | 136 |
infectious disease | 134 |
dipeptidyl peptidase | 134 |
influenza viruses | 133 |
significantly higher | 132 |
chain reaction | 130 |
weaned pigs | 130 |
pandemic influenza | 130 |
previously described | 129 |
epithelial cells | 129 |
cell line | 129 |
polymerase chain | 128 |
lung cancer | 128 |
epidemic diarrhea | 128 |
control group | 124 |
nucleic acid | 124 |
disaster risk | 124 |
respiratory disease | 124 |
antibacterial activity | 123 |
diarrhea virus | 123 |
bronchitis virus | 123 |
endoplasmic reticulum | 121 |
specific cd | 120 |
immunodeficiency virus | 118 |
statistically significant | 116 |
pcr assay | 115 |
previous studies | 114 |
dna aptamers | 111 |
tract infections | 110 |
human coronavirus | 109 |
lower respiratory | 108 |
significant difference | 106 |
hong kong | 105 |
cancer cells | 105 |
inflammatory response | 104 |
cell culture | 104 |
human metapneumovirus | 104 |
herpes simplex | 100 |
neutralizing antibodies | 100 |
reverse transcription | 99 |
suckling pigs | 98 |
healthcare workers | 97 |
hemorrhagic fever | 96 |
cell surface | 96 |
described previously | 96 |
virus infections | 95 |
time rt | 95 |
influenza vaccine | 95 |
nucleic acids | 95 |
respiratory infections | 94 |
heart failure | 94 |
human immunodeficiency | 93 |
monoclonal antibodies | 93 |
important role | 93 |
pi ka | 92 |
virus type | 92 |
nervous system | 92 |
risk reduction | 91 |
innate immunity | 90 |
world health | 90 |
cell responses | 90 |
monoclonal antibody | 89 |
cell death | 89 |
sense rna | 89 |
host cell | 89 |
plasma membrane | 89 |
respiratory distress | 88 |
bases derived | 88 |
disease virus | 87 |
protease inhibitors | 87 |
phylogenetic analysis | 87 |
virus disease | 86 |
epidemic threshold | 86 |
simplex virus | 86 |
rate coefficient | 86 |
fractal dimension | 85 |
systematic review | 85 |
intensive care | 85 |
significant differences | 84 |
closely related | 84 |
highly pathogenic | 84 |
nk cell | 83 |
respiratory illness | 83 |
health organization | 83 |
fractal analysis | 83 |
infection control | 83 |
binding rate | 83 |
cleavage site | 82 |
central nervous | 82 |
saudi arabia | 81 |
viral proteins | 81 |
blood pressure | 81 |
antiviral activity | 81 |
body weight | 81 |
results suggest | 79 |
mental health | 78 |
influenza pandemic | 78 |
upper respiratory | 78 |
intravenous immunoglobulin | 77 |
respiratory virus | 77 |
binding site | 77 |
room temperature | 77 |
disaster management | 76 |
animal models | 76 |
data set | 76 |
phenolic mannich | 76 |
high risk | 75 |
neutrophil elastase | 75 |
transmissible gastroenteritis | 75 |
time points | 74 |
significantly lower | 74 |
least one | 74 |
peptidase iv | 73 |
life technologies | 73 |
peripheral blood | 73 |
pcr assays | 73 |
two groups | 73 |
cancer cell | 73 |
western blot | 73 |
risk factor | 72 |
mic values | 72 |
genetic diversity | 72 |
dna sequences | 72 |
like particles | 72 |
wide range | 71 |
clinical trial | 71 |
nonhuman primates | 71 |
nk cells | 71 |
cell activation | 71 |
study period | 70 |
crystal structure | 70 |
nucleocapsid protein | 70 |
i ifn | 70 |
breast cancer | 70 |
clinical isolates | 69 |
west africa | 69 |
rfid technology | 69 |
hospitalized patients | 68 |
dengue virus | 68 |
ng ml | 68 |
high levels | 68 |
tissue culture | 67 |
additional file | 67 |
age group | 67 |
viral dna | 67 |
cd cd | 67 |
inflammatory cytokines | 67 |
binding protein | 67 |
dna aptamer | 67 |
disease control | 67 |
vero cells | 67 |
mutation rate | 67 |
sars coronavirus | 66 |
mannich reaction | 66 |
results showed | 66 |
large number | 65 |
infectious agents | 65 |
naturally occurring | 65 |
per year | 65 |
median age | 65 |
influenza vaccines | 65 |
sequence analysis | 64 |
spike protein | 64 |
stem cell | 64 |
lymph nodes | 64 |
class ii | 64 |
well plates | 64 |
statistical analysis | 63 |
total number | 63 |
negative control | 63 |
mouse model | 63 |
seasonal influenza | 63 |
protease inhibitor | 63 |
cfu ml | 63 |
infected patients | 63 |
convalescent plasma | 63 |
cellular proteins | 63 |
vesicular stomatitis | 63 |
widely used | 63 |
three times | 63 |
gut microbiota | 63 |
cut sites | 63 |
recent years | 62 |
blood samples | 62 |
isothermal amplification | 62 |
cell proliferation | 62 |
tract infection | 62 |
type lectin | 62 |
age groups | 62 |
complete genome | 62 |
flow cytometry | 62 |
streptococcus pneumoniae | 61 |
reverse transcriptase | 61 |
pulmonary disease | 61 |
specific antibodies | 61 |
life cycle | 61 |
human papillomavirus | 61 |
current study | 61 |
determine whether | 60 |
novel coronavirus | 60 |
recent study | 60 |
determined using | 60 |
commonly used | 60 |
side effects | 60 |
natural killer | 60 |
type ii | 60 |
previously reported | 60 |
newcastle disease | 60 |
risk management | 60 |
mammalian cells | 60 |
antibody responses | 60 |
rna polymerase | 59 |
united nations | 59 |
respiratory pathogens | 59 |
multiplex pcr | 59 |
carbon nanotubes | 59 |
multiple sclerosis | 59 |
phase i | 59 |
authors declare | 59 |
bacterial infections | 59 |
several studies | 58 |
antibody response | 58 |
protein expression | 58 |
acetic acid | 58 |
years old | 58 |
gastroenteritis virus | 58 |
virus strains | 58 |
live attenuated | 58 |
increased risk | 58 |
adaptive immune | 58 |
treated cells | 57 |
receptor binding | 57 |
structural proteins | 57 |
genome sequence | 56 |
developing countries | 56 |
influenza infection | 56 |
viral genome | 56 |
host cells | 55 |
marburg virus | 55 |
stomatitis virus | 55 |
logistic regression | 55 |
north carolina | 55 |
endothelial cells | 55 |
clinical samples | 55 |
total rna | 55 |
young children | 55 |
significantly different | 55 |
distress syndrome | 55 |
united kingdom | 54 |
type lectins | 54 |
viral loads | 54 |
highly conserved | 54 |
human coronaviruses | 54 |
time point | 54 |
mean age | 54 |
influenza pneumonia | 54 |
infected cats | 54 |
amine reagents | 54 |
also known | 54 |
hsp isoforms | 53 |
disease severity | 53 |
acquired pneumonia | 53 |
coronavirus infection | 53 |
dna vaccines | 53 |
porcine reproductive | 53 |
global health | 53 |
resistant strains | 53 |
rna virus | 52 |
mrna levels | 52 |
respiratory symptoms | 52 |
recent studies | 52 |
barr virus | 52 |
syndrome virus | 52 |
like receptor | 52 |
influenza vaccination | 52 |
also found | 52 |
serum samples | 52 |
data sets | 52 |
results indicate | 52 |
type diabetes | 52 |
protective immunity | 52 |
binding affinity | 52 |
goat anti | 52 |
transcription factor | 51 |
case report | 51 |
serine protease | 51 |
strains isolated | 51 |
antimicrobial activity | 51 |
animal model | 51 |
graphical representation | 51 |
small intestine | 51 |
chronic obstructive | 51 |
tcov isolates | 51 |
obstructive pulmonary | 50 |
human bocavirus | 50 |
chikungunya virus | 50 |
adverse events | 50 |
mass spectrometry | 50 |
dromedary camels | 50 |
binding sites | 50 |
university hospital | 50 |
two different | 49 |
virus particles | 49 |
dendritic cell | 49 |
lung disease | 49 |
growth factor | 49 |
mediated isothermal | 49 |
posterior predictive | 49 |
factors associated | 49 |
clostridium difficile | 49 |
pasteurella multocida | 49 |
family members | 48 |
cell immune | 48 |
rheumatoid arthritis | 48 |
previous study | 48 |
complement activation | 48 |
transplant recipients | 48 |
quantitative real | 48 |
copies ml | 48 |
hiv infection | 48 |
gluconacetobacter diazotrophicus | 48 |
antigen presentation | 48 |
cell types | 48 |
respiratory viral | 48 |
dna vaccine | 48 |
standard deviation | 48 |
cancer patients | 48 |
clinical presentation | 47 |
environmental factors | 47 |
negative sense | 47 |
inflammatory responses | 47 |
molecular epidemiology | 47 |
significantly reduced | 47 |
supplementary material | 47 |
substitution model | 47 |
health security | 47 |
viral diseases | 47 |
prospective study | 47 |
study showed | 47 |
cell transplantation | 47 |
computed tomography | 47 |
mortality rate | 47 |
new zealand | 46 |
cov infection | 46 |
cell cycle | 46 |
like receptors | 46 |
drug resistance | 46 |
electron microscopy | 46 |
cells infected | 46 |
trex bcbl | 46 |
dependent manner | 46 |
isolated ns | 46 |
study group | 46 |
analyzed using | 46 |
protein sequences | 46 |
oxidative stress | 46 |
care unit | 45 |
three different | 45 |
viral protein | 45 |
stranded rna | 45 |
gel electrophoresis | 45 |
signaling pathways | 45 |
log cfu | 45 |
one study | 45 |
clinical improvement | 45 |
severe respiratory | 45 |
retrospective study | 45 |
first time | 45 |
viral entry | 44 |
pro complex | 44 |
diabetes mellitus | 44 |
differentially expressed | 44 |
pregnant women | 44 |
drug delivery | 44 |
sierra leone | 44 |
memory cd | 44 |
methyl bromide | 44 |
pathogenic avian | 44 |
antibody titers | 44 |
lg ml | 44 |
bovine serum | 44 |
lymph node | 44 |
may provide | 44 |
persistent infection | 44 |
host immune | 44 |
reactive protein | 44 |
rta cells | 44 |
bursal disease | 43 |
neutralizing antibody | 43 |
bactericidal activity | 43 |
physical examination | 43 |
different types | 43 |
dna polymerase | 43 |
emerging infectious | 43 |
positive sense | 43 |
significantly increased | 43 |
viral particles | 43 |
molecular weight | 43 |
infectious bursal | 43 |
vaccine development | 43 |
therapeutic antibodies | 43 |
infected mice | 43 |
pcr products | 43 |
bacterial infection | 43 |
emergency department | 43 |
lung injury | 43 |
rapid detection | 43 |
traumatic stress | 42 |
target cells | 42 |
bacterial pathogens | 42 |
confidence interval | 42 |
antimicrobial resistance | 42 |
incubation period | 42 |
fusion protein | 42 |
expression levels | 42 |
cut site | 42 |
i molecules | 42 |
data points | 42 |
clinical data | 42 |
may lead | 42 |
even though | 42 |
antimicrobial susceptibility | 42 |
ebov infection | 42 |
heart rate | 42 |
cell frequencies | 42 |
clinical features | 42 |
respiratory infection | 42 |
high level | 41 |
tumor cells | 41 |
emergency response | 41 |
sequence alignment | 41 |
ketonic mannich | 41 |
long term | 41 |
sequence data | 41 |
clock model | 41 |
genome sequences | 41 |
immune activation | 41 |
ge healthcare | 41 |
cytokine production | 41 |
intermediate compartment | 41 |
antifungal activity | 41 |
mm tris | 41 |
also observed | 41 |
mortality rates | 41 |
health system | 41 |
health services | 41 |
analysis showed | 41 |
control measures | 41 |
prostate cancer | 41 |
serum levels | 41 |
aliphatic amines | 41 |
virus titer | 41 |
quantum moves | 41 |
pg ml | 40 |
controlled trial | 40 |
effector functions | 40 |
left ventricular | 40 |
gene sequences | 40 |
immune complexes | 40 |
wild type | 40 |
patients infected | 40 |
blood cultures | 40 |
specific antibody | 40 |
real time | 40 |
dairy calves | 39 |
resistant staphylococcus | 39 |
cell wall | 39 |
hospitalized children | 39 |
member states | 39 |
positive samples | 39 |
lymphocyte count | 39 |
severe disease | 39 |
food system | 39 |
another study | 39 |
cardiac arrest | 39 |
infected suckling | 39 |
climate change | 39 |
urinary tract | 39 |
bovine coronavirus | 39 |
transmission rate | 39 |
sample size | 39 |
open reading | 39 |
porcine circovirus | 39 |
infected animals | 39 |
animal lectins | 39 |
adverse effects | 39 |
streptococcus suis | 39 |
like protease | 39 |
better understanding | 39 |
less potent | 38 |
data collection | 38 |
south korea | 38 |
also showed | 38 |
amine reagent | 38 |
clock models | 38 |
susceptibility testing | 38 |
dna replication | 38 |
high affinity | 38 |
see table | 38 |
dna sequence | 38 |
ifn signaling | 38 |
derivatives synthesis | 38 |
autoimmune diseases | 38 |
nitric oxide | 38 |
alveolar macrophages | 38 |
pedv infection | 38 |
immune cells | 38 |
may help | 38 |
acid sequence | 38 |
antibiotic treatment | 38 |
commercially available | 38 |
serine proteases | 38 |
medical records | 38 |
nile virus | 38 |
days post | 38 |
small number | 38 |
duplex undp | 38 |
western blotting | 38 |
naturally infected | 38 |
i interferon | 38 |
mycobacterium tuberculosis | 38 |
otitis media | 38 |
ebola outbreak | 37 |
standard precautions | 37 |
membrane protein | 37 |
nipah virus | 37 |
phylogenetic trees | 37 |
west nile | 37 |
protein kinase | 37 |
encephalitis virus | 37 |
pseudomonas aeruginosa | 37 |
cell viability | 37 |
infected weaned | 37 |
galnac utilization | 37 |
hepatitis virus | 37 |
antibiotic therapy | 37 |
virus titers | 37 |
online version | 37 |
necrosis factor | 37 |
dependent rna | 37 |
quantitative pcr | 37 |
host disease | 36 |
ovarian cancer | 36 |
significant increase | 36 |
health education | 36 |
human respiratory | 36 |
cohort study | 36 |
clinical manifestations | 36 |
gastrointestinal tract | 36 |
membrane fusion | 36 |
immunosorbent assay | 36 |
infl uenza | 36 |
cells expressing | 36 |
presenting cells | 36 |
viral pathogens | 36 |
hospital stay | 36 |
biological activity | 36 |
statistical significance | 36 |
feline coronavirus | 36 |
weight loss | 36 |
significant reduction | 36 |
obtained using | 36 |
antimicrobial therapy | 36 |
quality control | 36 |
canonical cleavage | 36 |
double mannich | 36 |
clinical disease | 36 |
fecal samples | 36 |
carbon dioxide | 36 |
galn galnac | 35 |
blood culture | 35 |
democratic republic | 35 |
disaster reduction | 35 |
inhibitory activity | 35 |
human health | 35 |
differential diagnosis | 35 |
high prevalence | 35 |
active site | 35 |
insect cells | 35 |
dub activity | 35 |
patients receiving | 35 |
cellular immune | 35 |
adaptive immunity | 35 |
retinal detachment | 35 |
turkey coronavirus | 35 |
molecular mechanisms | 35 |
delivery system | 35 |
infectious virus | 35 |
nucleotide sequences | 35 |
heat shock | 35 |
structural protein | 35 |
antimicrobial agents | 35 |
dpp i | 35 |
among patients | 35 |
early stage | 35 |
three independent | 35 |
informed consent | 35 |
secondary aliphatic | 35 |
among children | 35 |
cells treated | 35 |
egg yolk | 35 |
animal health | 35 |
respiratory failure | 35 |
fever virus | 35 |
legal preparedness | 35 |
data suggest | 35 |
internal control | 34 |
differential diagnoses | 34 |
cells using | 34 |
disease progression | 34 |
lung tissues | 34 |
red blood | 34 |
feline infectious | 34 |
pst isolates | 34 |
case study | 34 |
nested pcr | 34 |
proteomic analysis | 34 |
high mortality | 34 |
world bank | 34 |
may play | 34 |
protein levels | 34 |
healthy dogs | 34 |
antibiotic use | 34 |
proinflammatory cytokines | 34 |
phase ii | 34 |
marginal infections | 34 |
ms ms | 34 |
per day | 34 |
infectious peritonitis | 34 |
lytic replication | 34 |
cell response | 34 |
acute phase | 34 |
may contribute | 34 |
cell help | 34 |
cell lysates | 34 |
cerebrospinal fluid | 34 |
high temperature | 34 |
member countries | 34 |
well tolerated | 33 |
competing interests | 33 |
biological evaluation | 33 |
dna sequencing | 33 |
cardiovascular disease | 33 |
technical assistance | 33 |
parainfluenza virus | 33 |
binding lectin | 33 |
taken together | 33 |
significantly associated | 33 |
japanese encephalitis | 33 |
human adenovirus | 33 |
like pestivirus | 33 |
exact test | 33 |
tgev infection | 33 |
blood cell | 33 |
genomic rna | 33 |
lg mg | 33 |
clinically relevant | 33 |
converting enzyme | 33 |
gene therapy | 33 |
sir model | 33 |
signaling pathway | 33 |
simultaneous detection | 33 |
lung consolidation | 33 |
european countries | 33 |
south africa | 33 |
antibiotic resistance | 33 |
last years | 33 |
sox cut | 33 |
survival time | 33 |
antiviral drugs | 33 |
national institute | 33 |
hematopoietic stem | 33 |
like peptide | 32 |
health systems | 32 |
enzymatic activity | 32 |
guinea pigs | 32 |
sendai virus | 32 |
ic values | 32 |
cytotoxic activity | 32 |
icu admission | 32 |
sickle cell | 32 |
way anova | 32 |
pedv rna | 32 |
diagnostic tests | 32 |
rna species | 32 |
maternal antibodies | 32 |
years ago | 32 |
rna replication | 32 |
antimycobacterial activity | 32 |
capsid protein | 32 |
cell cultures | 32 |
regression analysis | 32 |
clinical symptoms | 32 |
empirical data | 32 |
protein synthesis | 32 |
cell membrane | 32 |
lysis buffer | 32 |
clinical characteristics | 32 |
fatty acid | 32 |
hek cells | 32 |
na levertransplantatie | 32 |
future studies | 32 |
low levels | 32 |
complement system | 32 |
antiviral response | 32 |
terminal domain | 32 |
broad spectrum | 32 |
disease transmission | 32 |
liver transplantation | 32 |
mechanical ventilation | 32 |
culture media | 32 |
one case | 31 |
vvibdv strains | 31 |
year old | 31 |
macrolide resistance | 31 |
avian infectious | 31 |
clinical studies | 31 |
inflammatory activity | 31 |
virus isolation | 31 |
laboratory animal | 31 |
national university | 31 |
tumor necrosis | 31 |
cell activity | 31 |
clinical outcome | 31 |
canine distemper | 31 |
mab igg | 31 |
molecular characterization | 31 |
severe pneumonia | 31 |
organ failure | 31 |
heart disease | 31 |
severity scores | 31 |
carbohydrate microarrays | 31 |
critical role | 31 |
novel human | 31 |
inhibitory effect | 31 |
pst population | 31 |
virus neutralization | 31 |
results obtained | 31 |
patient care | 31 |
key role | 31 |
human population | 31 |
within days | 31 |
blot analysis | 31 |
randomized controlled | 31 |
genomic dna | 31 |
fc receptor | 31 |
hand hygiene | 31 |
direct contact | 31 |
genome replication | 31 |
binding specificity | 31 |
cell adhesion | 31 |
phylogenetic tree | 31 |
buffered saline | 31 |
cysteine protease | 31 |
signifi cant | 31 |
human serum | 31 |
respiratory rate | 31 |
west african | 31 |
bovine viral | 30 |
field isolates | 30 |
clinical practice | 30 |
body condition | 30 |
st cells | 30 |
psychological trauma | 30 |
natural disasters | 30 |
virus strain | 30 |
less likely | 30 |
much higher | 30 |
vaccine strain | 30 |
protective equipment | 30 |
viral titers | 30 |
expressing cells | 30 |
acetobacter diazotrophicus | 30 |
also used | 30 |
virus entry | 30 |
adult patients | 30 |
virus glycoprotein | 30 |
economic losses | 30 |
lymphoid tissue | 30 |
red cross | 30 |
human infection | 30 |
tissue damage | 30 |
mediated immune | 30 |
virus vaccine | 30 |
molecular clock | 30 |
patients treated | 30 |
deficient mice | 30 |
zealand white | 30 |
critically ill | 30 |
infected avian | 30 |
autoimmune disease | 30 |
generation sequencing | 30 |
lung function | 30 |
pediatric patients | 30 |
underlying disease | 30 |
hela cells | 30 |
protein response | 30 |
linked immunosorbent | 30 |
growth rate | 30 |
small molecule | 30 |
small molecules | 30 |
human infected | 30 |
dna viruses | 30 |
pneumonia caused | 29 |
unfolded protein | 29 |
genome size | 29 |
rrna gene | 29 |
pi kb | 29 |
specific igg | 29 |
fatality rate | 29 |
natural hazards | 29 |
veterinary medicine | 29 |
lupus erythematosus | 29 |
severe influenza | 29 |
vitro activity | 29 |
mg dl | 29 |
cysteine proteases | 29 |
jhmv infection | 29 |
genome segments | 29 |
secondary structure | 29 |
fungal infections | 29 |
myocardial infarction | 29 |
secretory pathway | 29 |
relatively low | 29 |
highly variable | 29 |
applied biosystems | 29 |
cchfv nucleoprotein | 29 |
mitral valve | 29 |
antiretroviral therapy | 29 |
rna genome | 29 |
membrane proteins | 29 |
ali ards | 29 |
cell disease | 29 |
human influenza | 29 |
susceptible individuals | 29 |
binding proteins | 29 |
hpa phe | 29 |
infected individuals | 29 |
distemper virus | 29 |
mm nacl | 29 |
persistently infected | 29 |
bd biosciences | 29 |
bovine respiratory | 29 |
many different | 29 |
also reported | 29 |
epidemiological studies | 29 |
leukemia virus | 29 |
signal peptide | 29 |
signal transduction | 29 |
canine coronavirus | 29 |
analysis revealed | 28 |
secondary antibody | 28 |
healthy cats | 28 |
rna interference | 28 |
macular degeneration | 28 |
major cause | 28 |
wide variety | 28 |
treatment groups | 28 |
acute infection | 28 |
molecular methods | 28 |
feline sporotrichosis | 28 |
military recruits | 28 |
studies showed | 28 |
anticonvulsant activity | 28 |
cytoplasmic tail | 28 |
vp protein | 28 |
experimentally infected | 28 |
electronic microarray | 28 |
transcriptional units | 28 |
acid bacteria | 28 |
resistant isolates | 28 |
studies reported | 28 |
care workers | 28 |
different concentrations | 28 |
fatty acids | 28 |
igg antibodies | 28 |
nursing students | 28 |
host innate | 28 |
disk diffusion | 28 |
similar results | 28 |
single infections | 28 |
one hundred | 28 |
stem cells | 28 |
hiv protease | 28 |
causative agent | 28 |
reading frame | 28 |
human rights | 28 |
remains unclear | 28 |
mutation rates | 28 |
virulence genes | 28 |
false positive | 28 |
mouse hepatitis | 28 |
high sensitivity | 28 |
antigen processing | 28 |
agar plates | 28 |
pcr using | 28 |
medicinal chemistry | 28 |
will help | 28 |
patients received | 28 |
saharan africa | 28 |
per group | 27 |
animal medicine | 27 |
haemophilus influenzae | 27 |
viral genomes | 27 |
blood group | 27 |
mouse models | 27 |
infections caused | 27 |
enveloped viruses | 27 |
respiratory diseases | 27 |
circovirus type | 27 |
well known | 27 |
international health | 27 |
human igg | 27 |
plant growth | 27 |
virus ns | 27 |
personal protective | 27 |
porcine respiratory | 27 |
peritonsillar abscess | 27 |
dairy herds | 27 |
vaccine strains | 27 |
tract disease | 27 |
kg day | 27 |
care providers | 27 |
des chauves | 27 |
sox cleavage | 27 |
protective effect | 27 |
identifi ed | 27 |
viral respiratory | 27 |
mice infected | 27 |
induced apoptosis | 27 |
renal failure | 27 |
viral envelope | 27 |
correlation coefficient | 27 |
early stages | 27 |
biosensor surface | 27 |
disease outbreak | 27 |
patients without | 27 |
sialic acid | 27 |
colon cancer | 27 |
recombinant proteins | 27 |
growth inhibition | 27 |
research complications | 27 |
protein gene | 27 |
vaccine candidate | 27 |
associated herpesvirus | 27 |
different time | 27 |
positive results | 27 |
fi rst | 27 |
airborne transmission | 27 |
phylogenetic analyses | 27 |
diffusion method | 27 |
reactivated cells | 27 |
maximum likelihood | 27 |
stranded dna | 26 |
kshv lytic | 26 |
binding domain | 26 |
cm herds | 26 |
north america | 26 |
virus rna | 26 |
also shown | 26 |
close contact | 26 |
viral diarrhea | 26 |
hiv aids | 26 |
liver disease | 26 |
alternative pathway | 26 |
pao fio | 26 |
reactive oxygen | 26 |
ravn gp | 26 |
immunocompromised patients | 26 |
lung tissue | 26 |
nonstructural protein | 26 |
recent advances | 26 |
lawsonia intracellularis | 26 |
pattern recognition | 26 |
based vaccines | 26 |
general population | 26 |
risk assessment | 26 |
drug discovery | 26 |
leptospira spp | 26 |
hcv rna | 26 |
study aimed | 26 |
coronavirus infections | 26 |
european union | 26 |
human transmission | 26 |
cd cells | 26 |
killer cells | 26 |
golgi intermediate | 26 |
children hospitalized | 26 |
mononuclear cells | 26 |
se excess | 26 |
detected using | 26 |
disease burden | 26 |
antiviral agents | 26 |
study found | 26 |
mucosal immunity | 26 |
clinical use | 26 |
human diseases | 26 |
animal welfare | 26 |
cell count | 26 |
data analysis | 26 |
cardiopulmonary resuscitation | 26 |
reperfusion injury | 26 |
reaction mixture | 26 |
disaster response | 26 |
tuberculosis patients | 26 |
per patient | 26 |
newly synthesized | 26 |
positive bacteria | 26 |
des virus | 26 |
using different | 26 |
specific immune | 26 |
laboratory rabbits | 25 |
age years | 25 |
million people | 25 |
isolation precautions | 25 |
results show | 25 |
i ifns | 25 |
chez les | 25 |
marburg viruses | 25 |
viral transcripts | 25 |
local food | 25 |
fold change | 25 |
fruit bats | 25 |
listeria monocytogenes | 25 |
terminal region | 25 |
reproduction number | 25 |
next generation | 25 |
sybr green | 25 |
blood cells | 25 |
virulence factors | 25 |
disease outbreaks | 25 |
positive control | 25 |
serum albumin | 25 |
systemic lupus | 25 |
sporothrix schenckii | 25 |
highly contagious | 25 |
antibody levels | 25 |
igg antibody | 25 |
coronavirus infectious | 25 |
attack rate | 25 |
genes encoding | 25 |
may result | 25 |
healthy individuals | 25 |
sequence alignments | 25 |
accession numbers | 25 |
confirmed cases | 25 |
results indicated | 25 |
bat species | 25 |
cell epitopes | 25 |
rfid tag | 25 |
case reports | 25 |
hydrogen bond | 25 |
acid sequences | 25 |
pro domain | 25 |
healthy adults | 25 |
linear regression | 25 |
time period | 25 |
coronavirus nl | 25 |
limited number | 25 |
chronic hepatitis | 25 |
tissue injury | 25 |
alexa fluor | 25 |
pedv strains | 25 |
comparative analysis | 25 |
test results | 25 |
plasmacytoid dendritic | 25 |
le virus | 25 |
first step | 25 |
primary care | 25 |
lymphoid tissues | 25 |
viral etiology | 25 |
emerging viruses | 25 |
copd exacerbations | 25 |
analysed using | 25 |
nucleotide sequence | 25 |
viral nucleic | 25 |
febrile respiratory | 25 |
income countries | 25 |
household members | 25 |
samples collected | 25 |
much lower | 25 |
coding regions | 25 |
les chauves | 25 |
previous reports | 25 |
renal function | 25 |
oxygen saturation | 25 |
resistance genes | 25 |
studies using | 25 |
transfected cells | 25 |
two cases | 25 |
hepg cells | 25 |
un agencies | 24 |
coronavirus nucleocapsid | 24 |
odds ratio | 24 |
body fat | 24 |
electrode surface | 24 |
confidence intervals | 24 |
glass opacities | 24 |
oral administration | 24 |
chalcone analogues | 24 |
antigen detection | 24 |
older patients | 24 |
heparan sulfate | 24 |
viet nam | 24 |
placebo group | 24 |
predictive value | 24 |
virus transmission | 24 |
young adults | 24 |
related activities | 24 |
outbreak sizes | 24 |
leading cause | 24 |
case series | 24 |
may affect | 24 |
np swab | 24 |
cell function | 24 |
food security | 24 |
bl mice | 24 |
crp concentration | 24 |
md simulations | 24 |
acute lower | 24 |
subcellular localization | 24 |
agar protein | 24 |
renal disease | 24 |
kshv rtcs | 24 |
alveolar proteinosis | 24 |
inflammatory bowel | 24 |
developed countries | 24 |
will also | 24 |
clinical specimens | 24 |
cell epitope | 24 |
cells within | 24 |
ttt ttt | 24 |
intervention group | 24 |
pleural effusion | 24 |
zoonotic disease | 24 |
dpp inhibition | 24 |
fish oil | 24 |
genome sequencing | 24 |
mental disorders | 24 |
cell receptor | 24 |
nitrogen fixing | 24 |
large scale | 24 |
currently available | 24 |
ebola hemorrhagic | 24 |
virus persistence | 24 |
antiviral therapy | 24 |
pulmonary embolism | 24 |
public policy | 24 |
virus hemagglutinin | 24 |
igm antibodies | 24 |
inactivated influenza | 24 |
serum concentrations | 24 |
iga antibodies | 24 |
previously published | 24 |
clinical status | 24 |
older adults | 24 |
clinical diagnosis | 24 |
may represent | 24 |
wild animals | 23 |
common cause | 23 |
last decade | 23 |
mycoplasma pneumoniae | 23 |
analysis using | 23 |
major histocompatibility | 23 |
recombinant virus | 23 |
cell clones | 23 |
bowel disease | 23 |
mean values | 23 |
infection rate | 23 |
cellular uptake | 23 |
cardiac injury | 23 |
small animal | 23 |
hydrogen bonds | 23 |
cov clpro | 23 |
guinea pig | 23 |
host defense | 23 |
wheat varieties | 23 |
helicobacter pylori | 23 |
recombinant human | 23 |
regulatory factor | 23 |
culture medium | 23 |
vivo studies | 23 |
envelope glycoproteins | 23 |
cellular protein | 23 |
multiple sequence | 23 |
diagnostic tools | 23 |
kidney disease | 23 |
valve disease | 23 |
infection may | 23 |
unit clerks | 23 |
coronavirus oc | 23 |
smooth muscle | 23 |
plasmodium falciparum | 23 |
three groups | 23 |
mouse monoclonal | 23 |
confidence level | 23 |
two distinct | 23 |
bactericidal effect | 23 |
serially diluted | 23 |
nitrogen fixation | 23 |
human dendritic | 23 |
many studies | 23 |
humoral immunity | 23 |
myeloid cells | 23 |
differ significantly | 23 |
marrow transplantation | 23 |
tcid ml | 23 |
infected pigs | 23 |
serum antibody | 23 |
protective immune | 23 |
rectal swabs | 23 |
phase clinical | 23 |
renilla luciferase | 23 |
mwcnt tyr | 23 |
vast majority | 23 |
aromatic ring | 23 |
rabbit polyclonal | 23 |
patients may | 23 |
oxygen species | 23 |
clinical course | 23 |
golgi complex | 23 |
clavulanic acid | 23 |
supplementary table | 23 |
diarrhoeal diseases | 23 |
cell carcinoma | 23 |
cells transfected | 23 |
numerical threshold | 23 |
hospital cardiac | 23 |
inclusion criteria | 23 |
candida albicans | 22 |
protein genes | 22 |
flow rate | 22 |
antibiotic susceptibility | 22 |
improvement criteria | 22 |
combined lymphocyte | 22 |
final manuscript | 22 |
study design | 22 |
bone resorption | 22 |
depleted mice | 22 |
stimulated genes | 22 |
genetic variation | 22 |
human infections | 22 |
human disease | 22 |
thermo scientific | 22 |
differential expression | 22 |
different genotypes | 22 |
single dose | 22 |
pulmonary alveolar | 22 |
congestive heart | 22 |
epidemic size | 22 |
single nucleotide | 22 |
protective antigen | 22 |
dp dt | 22 |
enterococcus faecalis | 22 |
protein sequence | 22 |
pcr method | 22 |
antibiotic consumption | 22 |
reverse genetics | 22 |
hcv ns | 22 |
patients presenting | 22 |
host range | 22 |
prolyl endopeptidase | 22 |
chest radiograph | 22 |
epidemic models | 22 |
white blood | 22 |
feline immunodeficiency | 22 |
igg concentrates | 22 |
chest syndrome | 22 |
sex differences | 22 |
vaccine candidates | 22 |
new york | 22 |
adenosine deaminase | 22 |
fetal bovine | 22 |
literature review | 22 |
acute lung | 22 |
clinically significant | 22 |
mcg ml | 22 |
adenovirus type | 22 |
decision making | 22 |
cell type | 22 |
acute chest | 22 |
coli strains | 22 |
performed according | 22 |
calculated using | 22 |
schiff bases | 22 |
infections among | 22 |
inflammatory diseases | 22 |
er stress | 22 |
evidence suggests | 22 |
imi cis | 22 |
respiratory specimens | 22 |
supporting information | 22 |
first report | 22 |
gene sequence | 22 |
rna aptamers | 22 |
respiratory coronavirus | 22 |
disease emergence | 22 |
plasmid dna | 22 |
attenuated vaccines | 22 |
royal canin | 22 |
hsp inhibitors | 22 |
reference drugs | 22 |
utilization pathway | 22 |
immunoglobulin therapy | 22 |
recently reported | 22 |
teaching hospital | 22 |
higher levels | 22 |
fractal dimensions | 22 |
nonstructural proteins | 22 |
multiple organ | 22 |
swab sample | 22 |
high degree | 22 |
adhesion molecules | 22 |
dna vaccination | 22 |
transcription factors | 22 |
generated using | 22 |
basic reproduction | 22 |
pedv strain | 22 |
genomic sequence | 22 |
secondary bacterial | 22 |
pcr amplification | 22 |
infected rabbits | 21 |
model adequacy | 21 |
population clusters | 21 |
ards patients | 21 |
surface plasmon | 21 |
novel mechanism | 21 |
ebola epidemic | 21 |
dissociation rate | 21 |
acute inflammatory | 21 |
cysteine residues | 21 |
time reverse | 21 |
rpa assays | 21 |
authors read | 21 |
contains supplementary | 21 |
prolyl oligopeptidase | 21 |
cell signaling | 21 |
high rate | 21 |
associated pneumonia | 21 |
evaluated using | 21 |
two weeks | 21 |
conjugated goat | 21 |
pulmonary complications | 21 |
assessed using | 21 |
sore throat | 21 |
coding region | 21 |
alkaline phosphatase | 21 |
muscular dystrophy | 21 |
small intestinal | 21 |
diabetes insipidus | 21 |
pst field | 21 |
also detected | 21 |
systemic inflammatory | 21 |
two decades | 21 |
mean value | 21 |
independent risk | 21 |
viral shedding | 21 |
virus vaccines | 21 |
essential role | 21 |
immune function | 21 |
impedance signal | 21 |
zoonotic diseases | 21 |
virus evolution | 21 |
airway epithelial | 21 |
bronchoalveolar lavage | 21 |
factors may | 21 |
walled carbon | 21 |
i production | 21 |
hcv infection | 21 |
proinflammatory cytokine | 21 |
specific primers | 21 |
high viral | 21 |
enteric disease | 21 |
reservoir hosts | 21 |
data shown | 21 |
clinical laboratory | 21 |
health emergency | 21 |
central african | 21 |
potent inhibitors | 21 |
ns protein | 21 |
yolk antibodies | 21 |
large numbers | 21 |
new class | 21 |
may occur | 21 |
ex vivo | 21 |
children years | 21 |
rabbit model | 21 |
primary infection | 21 |
statistical analyses | 21 |
serum igg | 21 |
higher risk | 21 |
least two | 21 |
early diagnosis | 21 |
systematic reviews | 21 |
bacterial pneumonia | 21 |
month follow | 21 |
times higher | 21 |
lamp assay | 21 |
test statistic | 21 |
square test | 21 |
every hours | 21 |
average number | 21 |
humoral immune | 21 |
bevs platform | 21 |
high resolution | 21 |
using real | 21 |
cellular processes | 21 |
analgesic activity | 21 |
significant decrease | 21 |
negative bacteria | 21 |
sustainable development | 21 |
pulmonary function | 21 |
lymphotropic virus | 21 |
first reported | 21 |
antibody titer | 21 |
dans les | 21 |
posttraumatic stress | 21 |
fusion peptide | 21 |
one week | 21 |
tested positive | 21 |
poor outcome | 21 |
one patient | 20 |
biological activities | 20 |
solid organ | 20 |
src sirna | 20 |
acid residues | 20 |
study shows | 20 |
highly effective | 20 |
degree distribution | 20 |
natural infection | 20 |
viral spread | 20 |
cd hi | 20 |
sequence similarity | 20 |
viral antigens | 20 |
infect humans | 20 |
compared using | 20 |
several factors | 20 |
initial phase | 20 |
stress response | 20 |
vaccine design | 20 |
hospital admission | 20 |
expression vector | 20 |
serum cobalamin | 20 |
reading frames | 20 |
multiple viral | 20 |
early warning | 20 |
structural basis | 20 |
economic impact | 20 |
chronic diseases | 20 |
nine pathogens | 20 |
carbohydrate recognition | 20 |
crucial role | 20 |
secondary structures | 20 |
rpad index | 20 |
diseases caused | 20 |
nasopharyngeal aspirates | 20 |
positive blood | 20 |
mediated immunity | 20 |
clinical response | 20 |
based biosensor | 20 |
dans le | 20 |
virus detection | 20 |
written informed | 20 |
white rabbits | 20 |
langerhans cells | 20 |
independent experiments | 20 |
test strips | 20 |
protein spots | 20 |
acute otitis | 20 |
human airway | 20 |
related macular | 20 |
economic burden | 20 |
significantly decreased | 20 |
authorized users | 20 |
treatment options | 20 |
cell frequency | 20 |
laboratory animals | 20 |
positively associated | 20 |
cultured cells | 20 |
left atrial | 20 |
side chain | 20 |
low ph | 20 |
highly attenuated | 20 |
mrna expression | 20 |
field samples | 20 |
negative controls | 20 |
clinical significance | 20 |
dual pathogens | 20 |
ml kg | 20 |
stress disorder | 20 |
gene encoding | 20 |
invasive fungal | 20 |
early detection | 20 |
response rate | 20 |
two types | 20 |
coronavirus hku | 20 |
binding kinetics | 20 |
conserved among | 20 |
crisis management | 20 |
aminomethyl function | 20 |
amplified using | 20 |
contact tracing | 20 |
plasmon resonance | 20 |
continuous variables | 20 |
final epidemic | 20 |
branch lengths | 20 |
chronic kidney | 20 |
golgi transport | 20 |
pcr analysis | 20 |
pathogen patients | 20 |
virus challenge | 20 |
rsv infection | 20 |
showed good | 20 |
lmpc micelle | 20 |
polyclonal anti | 20 |
will require | 20 |
ova dna | 20 |
interferon regulatory | 20 |
clinical efficacy | 20 |
molecule inhibitors | 20 |
accessory proteins | 20 |
time quantitative | 20 |
therapeutic target | 20 |
mice immunized | 20 |
induced cell | 20 |
several years | 20 |
two strains | 20 |
findings suggest | 20 |
human cytomegalovirus | 19 |
sequence identity | 19 |
among others | 19 |
common cold | 19 |
cystic fibrosis | 19 |
genbank accession | 19 |
control groups | 19 |
asian countries | 19 |
feline herpesvirus | 19 |
high incidence | 19 |
knockout mice | 19 |
animal care | 19 |
enveloped virus | 19 |
ill household | 19 |
highly active | 19 |
cellular immunity | 19 |
genomic sequences | 19 |
ml min | 19 |
education intervention | 19 |
study also | 19 |
fi sh | 19 |
cell transplant | 19 |
combination therapy | 19 |
may reduce | 19 |
young dogs | 19 |
human monoclonal | 19 |
mediated protection | 19 |
uninfected suckling | 19 |
antiviral drug | 19 |
relative humidity | 19 |
secondary antibodies | 19 |
data indicate | 19 |
insect cell | 19 |
using primers | 19 |
considered statistically | 19 |
therapeutic potential | 19 |
pour les | 19 |
histocompatibility complex | 19 |
viral persistence | 19 |
luciferase reporter | 19 |
group i | 19 |
sensitivity analysis | 19 |
brain metastasis | 19 |
control cells | 19 |
liquid chromatography | 19 |
inflammatory cytokine | 19 |
severe clinical | 19 |
penetrating peptides | 19 |
ns protease | 19 |
tissue samples | 19 |
one day | 19 |
clinical relevance | 19 |
tumor cell | 19 |
based assays | 19 |
serum crp | 19 |
conformational changes | 19 |
viral testing | 19 |
human breast | 19 |
genetic variants | 19 |
central role | 19 |
whole blood | 19 |
general assembly | 19 |
humoral response | 19 |
infected cell | 19 |
interquartile range | 19 |
critical review | 19 |
rate coefficients | 19 |
young infants | 19 |
congo hemorrhagic | 19 |
strand rna | 19 |
viral glycoproteins | 19 |
adverse reactions | 19 |
cell lymphoma | 19 |
type iii | 19 |
antiviral responses | 19 |
medical care | 19 |
detection limit | 19 |
bacillus anthracis | 19 |
vaccine potency | 19 |
clinical study | 19 |
rna molecules | 19 |
nc group | 19 |
immune evasion | 19 |
human cases | 19 |
clinical outcomes | 19 |
novel mannich | 19 |
molecular patterns | 19 |
therapeutic efficacy | 19 |
extended data | 19 |
virus production | 19 |
national level | 19 |
surfactant protein | 19 |
abdominal pain | 19 |
haemorrhagic fever | 19 |
meteorological factors | 19 |
confirmed influenza | 19 |
faecal samples | 19 |
molecular evolutionary | 19 |
disease risk | 19 |
one dog | 19 |
read counts | 19 |
mucosal immune | 19 |
pfu ml | 19 |
slightly higher | 19 |
associated lymphoid | 19 |
marburg hemorrhagic | 19 |
horseradish peroxidase | 19 |
copy number | 19 |
increased significantly | 19 |
associated protein | 19 |
recognition receptors | 19 |
inhibitory concentration | 19 |
pcr product | 19 |
factor receptor | 19 |
working group | 19 |
measles virus | 19 |
vp gene | 19 |
without pneumonia | 19 |
linear model | 19 |
mouth disease | 19 |
electronic supplementary | 19 |
expression system | 19 |
golgi apparatus | 19 |
based vaccine | 19 |
reference laboratory | 19 |
software version | 19 |
using lipofectamine | 19 |
hot start | 18 |
broad range | 18 |
cell differentiation | 18 |
inflammatory mediators | 18 |
laboratory tests | 18 |
genetic characterization | 18 |
insulin resistance | 18 |
day group | 18 |
ifn response | 18 |
mice treated | 18 |
study population | 18 |
fold less | 18 |
medical staff | 18 |
primary human | 18 |
surface engineered | 18 |
may explain | 18 |
culture plates | 18 |
family coronaviridae | 18 |
population size | 18 |
igg group | 18 |
host factors | 18 |
intravenous administration | 18 |
antibody production | 18 |
case fatality | 18 |
human patients | 18 |
viruses isolated | 18 |
infection prevention | 18 |
uncorrelated lognormal | 18 |
pilot study | 18 |
study conducted | 18 |
likely due | 18 |
first year | 18 |
old female | 18 |
interferon signaling | 18 |
emergency preparedness | 18 |
considered significant | 18 |
antioxidant activity | 18 |
replication cycle | 18 |
subunit vaccines | 18 |
calf diarrhea | 18 |
human rhinovirus | 18 |
panax ginseng | 18 |
adhesion molecule | 18 |
homologous recombination | 18 |
table shows | 18 |
southern china | 18 |
ibv strains | 18 |
inspirotec sampler | 18 |
immune suppression | 18 |
avian flu | 18 |
colorectal cancer | 18 |
infective endocarditis | 18 |
mouse igg | 18 |
poorly understood | 18 |
health threats | 18 |
two patients | 18 |
par les | 18 |
passive transfer | 18 |
expression systems | 18 |
neutrophil recruitment | 18 |
swine flu | 18 |
washed three | 18 |
feline leukemia | 18 |
endocytic pathway | 18 |
santa cruz | 18 |
clpro cleavage | 18 |
hvr epb | 18 |
among different | 18 |
fruit bat | 18 |
extracellular matrix | 18 |
model selection | 18 |
er membrane | 18 |
final concentration | 18 |
molecular diagnostics | 18 |
positive cells | 18 |
severe diarrhea | 18 |
general intellect | 18 |
enterotoxigenic escherichia | 18 |
natural disaster | 18 |
showed significant | 18 |
target genes | 18 |
expression analysis | 18 |
rhesus macaques | 18 |
hbv vaccine | 18 |
assay using | 18 |
capacity building | 18 |
ill patients | 18 |
medical center | 18 |
clinical microbiology | 18 |
randomly selected | 18 |
klebsiella pneumoniae | 18 |
cell entry | 18 |
european commission | 18 |
serial dilutions | 18 |
transcription loop | 18 |
van een | 18 |
reticulum stress | 18 |
commonly transmitted | 18 |
epidermal growth | 18 |
significant correlation | 18 |
host interactions | 18 |
herpes virus | 18 |
positive dogs | 18 |
global burden | 18 |
pneumocystis carinii | 18 |
cipf whwts | 18 |
kg se | 18 |
positive patients | 18 |
candida activity | 18 |
delivery systems | 18 |
surveillance data | 18 |
relatively high | 18 |
viral antigen | 18 |
multiple viruses | 18 |
resistance rates | 18 |
coding sequence | 18 |
antibacterial agents | 18 |
study provides | 18 |
national institutes | 18 |
blood glucose | 18 |
relaxed clock | 18 |
expression profiles | 18 |
based methods | 18 |
cell growth | 18 |
fio combined | 18 |
south carolina | 18 |
available data | 18 |
protective efficacy | 18 |
nosocomial infection | 18 |
high concentrations | 18 |
effective treatment | 18 |
urine samples | 18 |
soft tissue | 18 |
decreased significantly | 18 |
pneumococcal vaccination | 18 |
conformational change | 18 |
epithelial cell | 18 |
prrsv nsp | 18 |
observational studies | 18 |
bcs model | 18 |
dengue fever | 18 |
health microbiology | 18 |
isolated individuals | 18 |
chest ct | 18 |
three cases | 18 |
envelope glycoprotein | 18 |
results demonstrate | 18 |
small animals | 18 |
biological processes | 18 |
biologically active | 18 |
dose intravenous | 18 |
high frequency | 18 |
lessons learned | 18 |
broadly neutralizing | 18 |
cell migration | 18 |
identified using | 18 |
mismatch repair | 18 |
control samples | 18 |
van der | 17 |
conducted using | 17 |
graphpad prism | 17 |
candidates derived | 17 |
cmv disease | 17 |
point mutations | 17 |
paw edema | 17 |
specific igm | 17 |
categorical variables | 17 |
experimental conditions | 17 |
hydroxyl group | 17 |
also evaluated | 17 |
ct scan | 17 |
gold standard | 17 |
low se | 17 |
new human | 17 |
like domain | 17 |
high dose | 17 |
policy makers | 17 |
iu ml | 17 |
streptococcus pyogenes | 17 |
like symptoms | 17 |
viral disease | 17 |
weight gain | 17 |
clinical findings | 17 |
food production | 17 |
coronavirus spike | 17 |
antitumor effects | 17 |
clinical presentations | 17 |
cervical cancer | 17 |
na activity | 17 |
first study | 17 |
nutritional se | 17 |
low risk | 17 |
first line | 17 |
disaster preparedness | 17 |
population cluster | 17 |
two separate | 17 |
different viruses | 17 |
multiplex real | 17 |
infections generated | 17 |
common respiratory | 17 |
drug development | 17 |
results suggested | 17 |
molecular analysis | 17 |
crystal structures | 17 |
control study | 17 |
host species | 17 |
recombinant viruses | 17 |
preliminary results | 17 |
use diversity | 17 |
severe mental | 17 |
southeast asia | 17 |
fold increase | 17 |
readily available | 17 |
frequently used | 17 |
nlrp inflammasome | 17 |
retrospective analysis | 17 |
multiplex rt | 17 |
project teams | 17 |
observational study | 17 |
activating fcgrs | 17 |
many viruses | 17 |
patients hospitalized | 17 |
dis doi | 17 |
virus genome | 17 |
dissociation kinetics | 17 |
financial support | 17 |
predictive data | 17 |
transmembrane domain | 17 |
rural areas | 17 |
glycoprotein gene | 17 |
virus isolated | 17 |
primer sets | 17 |
monte carlo | 17 |
randomized clinical | 17 |
antimicrobial activities | 17 |
exosome release | 17 |
fl exneri | 17 |
early phase | 17 |
health status | 17 |
sirna delivery | 17 |
clinical examination | 17 |
breed dogs | 17 |
signr expression | 17 |
rodent models | 17 |
laboratory findings | 17 |
urban areas | 17 |
transgenic mice | 17 |
carbohydrate antigens | 17 |
ddd tid | 17 |
fungal infection | 17 |
enzyme immunoassay | 17 |
foreign bodies | 17 |
reference strains | 17 |
chicken eggs | 17 |
north american | 17 |
conserved region | 17 |
sir epidemic | 17 |
cell counts | 17 |
killer cell | 17 |
cell lung | 17 |
accession number | 17 |
ifn production | 17 |
cytotoxic agents | 17 |
treated patients | 17 |
new species | 17 |
two viruses | 17 |
passive immunity | 17 |
molecular biology | 17 |
like structures | 17 |
galnac catabolism | 17 |
branch length | 17 |
tape measure | 17 |
copi coats | 17 |
tested using | 17 |
acute exacerbations | 17 |
laboratory diagnosis | 17 |
full length | 17 |
family burden | 17 |
pbs containing | 17 |
shock protein | 17 |
borne infections | 17 |
antibodies specific | 17 |
rats group | 17 |
viral clearance | 17 |
within hours | 17 |
chicken egg | 17 |
us department | 17 |
di giacomo | 17 |
targeted delivery | 17 |
domestic rabbits | 17 |
high morbidity | 17 |
extracted using | 17 |
classical pathway | 17 |
staff physicians | 17 |
experimental infection | 17 |
genetic background | 17 |
sars epidemic | 17 |
potential risk | 17 |
health emergencies | 17 |
possible role | 17 |
species level | 17 |
agar dilution | 17 |
infected group | 17 |
long axis | 17 |
low level | 17 |
crp concentrations | 17 |
review board | 17 |
viral co | 17 |
gatc sites | 17 |
reference strain | 16 |
trauma patients | 16 |
two major | 16 |
anthrax toxin | 16 |
influenza seasons | 16 |
rt pcr | 16 |
pigs compared | 16 |
containing antibodies | 16 |
binding properties | 16 |
different levels | 16 |
studies suggest | 16 |
relatively small | 16 |
disease caused | 16 |
neonatal infections | 16 |
data demonstrate | 16 |
stress granules | 16 |
four different | 16 |
fatal cases | 16 |
definitive diagnosis | 16 |
plasma cells | 16 |
virus vp | 16 |
mrna level | 16 |
tgev gene | 16 |
genome segment | 16 |
cells per | 16 |
cell membranes | 16 |
outer membrane | 16 |
met een | 16 |
fold dilutions | 16 |
vaccine delivery | 16 |
affected countries | 16 |
also demonstrated | 16 |
overall survival | 16 |
past years | 16 |
exon skipping | 16 |
dilution method | 16 |
laboratory data | 16 |
log likelihood | 16 |
current status | 16 |
kindly provided | 16 |
year period | 16 |
gold nanoparticles | 16 |
among adults | 16 |
type strains | 16 |
ifn system | 16 |
much less | 16 |
high quality | 16 |
study suggest | 16 |
least three | 16 |
effective vaccines | 16 |
bij een | 16 |
glycyrrhiza glabra | 16 |
molecular mass | 16 |
vvibdv lineage | 16 |
traumatic stressors | 16 |
signifi cantly | 16 |
respiratory illnesses | 16 |
first two | 16 |
medical conditions | 16 |
airway obstruction | 16 |
diarrhoeal cases | 16 |
coronavirus associated | 16 |
skin lesions | 16 |
one way | 16 |
lactic acid | 16 |
human pathogens | 16 |
uremic syndrome | 16 |
effi cacy | 16 |
study included | 16 |
expression data | 16 |
newly discovered | 16 |
sexual exploitation | 16 |
multivariate analysis | 16 |
respiratory pathogen | 16 |
adults hospitalized | 16 |
transmembrane proteins | 16 |
complement inhibitor | 16 |
air change | 16 |
versus weaned | 16 |
like virus | 16 |
pancreatic cancer | 16 |
vitro raised | 16 |
organ transplant | 16 |
virus nucleoprotein | 16 |
heat stress | 16 |
good agreement | 16 |
investigate whether | 16 |
six months | 16 |
organ cultures | 16 |
molecular basis | 16 |
adult respiratory | 16 |
right ventricular | 16 |
emergency nurses | 16 |
immune cell | 16 |
expression level | 16 |
mean degree | 16 |
assess whether | 16 |
adverse event | 16 |
phylogenetic marker | 16 |
study demonstrated | 16 |
reactive antibodies | 16 |
based study | 16 |
worker groups | 16 |
protein level | 16 |
studies conducted | 16 |
infected cases | 16 |
luciferase activity | 16 |
oryctolagus cuniculus | 16 |
patients undergoing | 16 |
res doi | 16 |
prepared using | 16 |
several types | 16 |
probably due | 16 |
controlled trials | 16 |
body fluids | 16 |
therapeutic agents | 16 |
ibdv strains | 16 |
emergency assistance | 16 |
chicken kidney | 16 |
gas vaccine | 16 |
research enterprise | 16 |
military personnel | 16 |
drug fluconazole | 16 |
past decade | 16 |
next manuscript | 16 |
close contacts | 16 |
peer review | 16 |
many years | 16 |
primary antibody | 16 |
cumulative attack | 16 |
viral genotypes | 16 |
near future | 16 |
enteric coronavirus | 16 |
i signaling | 16 |
also supported | 16 |
mini kit | 16 |
well plate | 16 |
early influenza | 16 |
rapid diagnosis | 16 |
free energy | 16 |
chloroquine hydroxychloroquine | 16 |
cell monolayers | 16 |
longitudinal study | 16 |
capsid proteins | 16 |
metapneumovirus infection | 16 |
newly emerging | 16 |
dual infections | 16 |
mycoplasma spp | 16 |
amine moiety | 16 |
environmental conditions | 16 |
pcr reaction | 16 |
reliable fit | 16 |
rna levels | 16 |
diagnostic test | 16 |
infection risk | 16 |
standard group | 16 |
igg concentrate | 16 |
po fio | 16 |
fc receptors | 16 |
rna synthesis | 16 |
agents synthesis | 16 |
coronavirus replication | 16 |
virus attachment | 16 |
also present | 16 |
infectious individuals | 16 |
diabetic patients | 16 |
neu ac | 16 |
rabbit igg | 16 |
circulating neutrophils | 16 |
diarrhoea virus | 16 |
will provide | 16 |
chronic infection | 16 |
previous work | 16 |
health regulations | 15 |
lognormal relaxed | 15 |
growth medium | 15 |
post infection | 15 |
abdominal ultrasound | 15 |
primers used | 15 |
bacterial meningitis | 15 |
approved drugs | 15 |
biomed central | 15 |
pneumococcal vaccine | 15 |
branching process | 15 |
prolonged los | 15 |
negative staphylococci | 15 |
animal studies | 15 |
multiple pathogens | 15 |
recently described | 15 |
biological replicates | 15 |
scoring system | 15 |
specific amplification | 15 |
i interferons | 15 |
cd expression | 15 |
different species | 15 |
igy antibodies | 15 |
virus isolates | 15 |
univariate analysis | 15 |
encountering ebola | 15 |
antimycobacterial agents | 15 |
allogeneic hematopoietic | 15 |
pulmonary arterial | 15 |
disaster prevention | 15 |
like particle | 15 |
systemic immune | 15 |
human colon | 15 |
positive predictive | 15 |
associated molecular | 15 |
viral capsid | 15 |
mice vaccinated | 15 |
embryonated chicken | 15 |
natural history | 15 |
infections may | 15 |
monocytes macrophages | 15 |
finishing pigs | 15 |
higher prevalence | 15 |
mannose receptor | 15 |
human cells | 15 |
coding sequences | 15 |
serum dc | 15 |
transition state | 15 |
binding activity | 15 |
igm antibody | 15 |
polyclonal antibody | 15 |
small cell | 15 |
protein interactions | 15 |
common feature | 15 |
plasma osmolality | 15 |
mg bid | 15 |
clinical management | 15 |
management system | 15 |
like proteases | 15 |
human gut | 15 |
also show | 15 |
basic reproductive | 15 |
microarray assay | 15 |
secondary amines | 15 |
simulated data | 15 |
human lung | 15 |
pcr rt | 15 |
host response | 15 |
antiviral effects | 15 |
human genome | 15 |
penetrating peptide | 15 |
envelope protein | 15 |
cellular responses | 15 |
fold higher | 15 |
climate factors | 15 |
significant changes | 15 |
transcriptional unit | 15 |
pcr results | 15 |
like viruses | 15 |
mers coronavirus | 15 |
potential benefits | 15 |
blood agar | 15 |
mm hepes | 15 |
transmission dynamics | 15 |
citizen science | 15 |
swinepox virus | 15 |
new genus | 15 |
may include | 15 |
retinoic acid | 15 |
detection rate | 15 |
intestinal disorders | 15 |
lesser extent | 15 |
displaced persons | 15 |
relationships among | 15 |
potential therapeutic | 15 |
induced activation | 15 |
preterm infants | 15 |
rfid based | 15 |
hospital discharge | 15 |
variability measure | 15 |
commonly associated | 15 |
spinal cord | 15 |
myeloid leukemia | 15 |
joining method | 15 |
marv ravn | 15 |
responses generated | 15 |
attenuated influenza | 15 |
local health | 15 |
detection methods | 15 |
antigen presenting | 15 |
analytical sensitivity | 15 |
important factor | 15 |
penicillium marneffei | 15 |
antimalarial activity | 15 |
disc diffusion | 15 |
pandemic potential | 15 |
small interfering | 15 |
supplementary data | 15 |
one hand | 15 |
three patients | 15 |
another important | 15 |
inactivated vaccine | 15 |
dna encoding | 15 |
antiviral effect | 15 |
severe cases | 15 |
children aged | 15 |
immune complex | 15 |
expression profile | 15 |
using two | 15 |
clinical impact | 15 |
bartonella spp | 15 |
infected individual | 15 |
related genes | 15 |
lymphocytic choriomeningitis | 15 |
papillomavirus type | 15 |
transcription polymerase | 15 |
broadly reactive | 15 |
transmembrane region | 15 |
qualitative research | 15 |
test result | 15 |
agarose gel | 15 |
bacterial strains | 15 |
infect dis | 15 |
described elsewhere | 15 |
hospitalised patients | 15 |
stool samples | 15 |
carbamate derivative | 15 |
pcr testing | 15 |
will likely | 15 |
influenza epidemics | 15 |
african countries | 15 |
putative cleavage | 15 |
rotavirus infection | 15 |
specific pathogen | 15 |
samples using | 15 |
cumulative cases | 15 |
cytometry analysis | 15 |
resistant bacteria | 15 |
sexual orientation | 15 |
broth microdilution | 15 |
cytokine response | 15 |
magnetic beads | 15 |
disease prevention | 15 |
tuberculosis control | 15 |
protein binding | 15 |
gp wing | 15 |
effector function | 15 |
virus nucleocapsid | 15 |
survival rate | 15 |
less active | 15 |
critical care | 15 |
previously healthy | 15 |
skeletal muscle | 15 |
significant association | 15 |
close proximity | 15 |
will allow | 15 |
total protein | 15 |
body temperature | 15 |
sample sizes | 15 |
system dynamics | 15 |
good activity | 15 |
clinical success | 15 |
less frequently | 15 |
transmembrane protein | 15 |
platelet aggregation | 15 |
pig model | 15 |
drug design | 15 |
situ hybridization | 15 |
excess i | 15 |
ic elements | 15 |
isg induction | 15 |
distantly related | 15 |
standard deviations | 15 |
evolutionary genetics | 15 |
better understand | 15 |
human vaccines | 15 |
stimulating factor | 15 |
proliferative enteropathy | 15 |
normal cells | 15 |
associated gene | 15 |
two days | 15 |
humanitarian assistance | 15 |
may become | 15 |
outbreak size | 15 |
activity comparable | 15 |
first case | 15 |
aqueous solubility | 15 |
avian coronaviruses | 15 |
numerous studies | 15 |
salmonella typhimurium | 15 |
rna binding | 15 |
social functioning | 15 |
located within | 15 |
take full | 15 |
spike glycoprotein | 15 |
studies show | 14 |
success rate | 14 |
day old | 14 |
viral pneumonia | 14 |
automated external | 14 |
may cause | 14 |
generation cephalosporins | 14 |
aureus strains | 14 |
milk samples | 14 |
several mannich | 14 |
lectin pathway | 14 |
group ii | 14 |
rabbit anti | 14 |
total population | 14 |
genetically diverse | 14 |
mes test | 14 |
shiga toxin | 14 |
excess ii | 14 |
human herpesvirus | 14 |
also tested | 14 |
weeks later | 14 |
right parasternal | 14 |
lgl lymphoma | 14 |
structural gameplay | 14 |
mg day | 14 |
provide protection | 14 |
cytopathic effect | 14 |
aureus isolates | 14 |
alpha beta | 14 |
gnotobiotic pigs | 14 |
three data | 14 |
phylogenetic relationships | 14 |
lead compound | 14 |
rescue dogs | 14 |
blood mononuclear | 14 |
per site | 14 |
common pathogens | 14 |
high cd | 14 |
months later | 14 |
gata deficiency | 14 |
fatal disease | 14 |
matrix protein | 14 |
emergency management | 14 |
study investigated | 14 |
cap severity | 14 |
highly sensitive | 14 |
cause severe | 14 |
prospective studies | 14 |
weaned infected | 14 |
protein concentrations | 14 |
error bars | 14 |
community acquired | 14 |
rate variation | 14 |
infectious complications | 14 |
major role | 14 |
bacterial cell | 14 |
core protein | 14 |
healthy volunteers | 14 |
traumatic brain | 14 |
mice challenged | 14 |
pandemic preparedness | 14 |
expression patterns | 14 |
beneficial effects | 14 |
marv gp | 14 |
central africa | 14 |
dengue infection | 14 |
acid extraction | 14 |
done using | 14 |
gene transfer | 14 |
medical facilities | 14 |
ch ch | 14 |
canine influenza | 14 |
remains unknown | 14 |
monoclonal anti | 14 |
multidrug resistant | 14 |
hsqc peaks | 14 |
institutional review | 14 |
medical students | 14 |
hemolytic anemia | 14 |
infectious period | 14 |
important roles | 14 |
marrow neutrophil | 14 |
complete segment | 14 |
cytokine storm | 14 |
thrombocytopenic purpura | 14 |
disease status | 14 |
hmf prediction | 14 |
squamous cell | 14 |
respiratory protection | 14 |
optical density | 14 |